참고문헌
- The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435. https://doi.org/10.1056/NEJM198706043162301
- The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
- Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-677. https://doi.org/10.1056/NEJM199209033271001
- ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685. https://doi.org/10.1016/S0140-6736(95)90865-X
- Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-2945. https://doi.org/10.1093/eurheartj/ehn416
- Task Force for Diagnosis and Treatment of Non-STSegment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, et al. Guidelines for the diagnosis and treatment of non-STsegment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-1660. https://doi.org/10.1093/eurheartj/ehm161
- Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004;109:8-13.
- Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-760. https://doi.org/10.1016/S0140-6736(02)09895-1
- Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906. https://doi.org/10.1056/NEJMoa032292
- McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006;47:726-733. https://doi.org/10.1016/j.jacc.2005.09.055
- Lee JH, Park HS, Chae SC, et al. Predictors of six-month major adverse cardiac events in 30-day survivors after acute myocardial infarction (from the Korea Acute Myocardial Infarction Registry). Am J Cardiol 2009;104:182-189. https://doi.org/10.1016/j.amjcard.2009.03.010
- Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-1513. https://doi.org/10.1053/euhj.2000.2305
- Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55. https://doi.org/10.1093/biomet/70.1.41
- Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-189. https://doi.org/10.1001/jama.295.2.180
- Hansen ML, Gislason GH, Kober L, et al. Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. Br J Clin Pharmacol 2008;65:217-223. https://doi.org/10.1111/j.1365-2125.2007.02991.x
- ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202-2212. https://doi.org/10.1161/01.CIR.97.22.2202
- Kohro T, Hayashi D, Okada Y, Yamazaki T, Nagai R; JCAD Investigators. Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study. Circ J 2007;71:1835-1840. https://doi.org/10.1253/circj.71.1835
- Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004;10:499-509. https://doi.org/10.1111/j.1365-2753.2003.00484.x
- Woo KS, Norris RM, Nicholls G. Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). Am J Cardiol 1995;75:967-968. https://doi.org/10.1016/S0002-9149(99)80703-6
피인용 문헌
- Angiotensin converting enzyme inhibitors remain the first treatment of choice vol.31, pp.2, 2016, https://doi.org/10.3904/kjim.2016.026
- 24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension vol.32, pp.6, 2017, https://doi.org/10.3904/kjim.2016.094
- Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction vol.6, pp.1, 2019, https://doi.org/10.1136/openhrt-2019-001010
- Angiotensin II Type 1 Receptor Blocker, Fimasartan, Reduces Vascular Smooth Muscle Cell Senescence by Inhibiting the CYR61 Signaling Pathway vol.49, pp.7, 2019, https://doi.org/10.4070/kcj.2018.0379
- Targeted Delivery of Recombinant Heat Shock Protein 27 to Cardiomyocytes Promotes Recovery from Myocardial Infarction vol.17, pp.6, 2016, https://doi.org/10.1021/acs.molpharmaceut.0c00192
- 2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction vol.50, pp.10, 2016, https://doi.org/10.4070/kcj.2020.0196
- Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers in Acute Coronary Syndrome and Preserved Ventricular Ejection Fraction vol.71, pp.10, 2016, https://doi.org/10.1177/0003319720946971